We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-3.64%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$546M
AUM Growth
-$150M
Cap. Flow
-$88.6M
Cap. Flow %
-16.21%
Top 10 Hldgs %
99.91%
Holding
13
New
1
Increased
–
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
FLXN
Flexion Therapeutics, Inc.
FLXN
+$47.1M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$48.9M
2
AKRO
Akero Therapeutics
AKRO
+$46.8M
3
VCYT icon
Veracyte
VCYT
+$31.2M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$304M 55.59%
3,631,656
-551,408
-13% -$48.9M
ADVM
2
DELISTED
Adverum Biotechnologies
ADVM
$72.1M 13.2%
700,389
– –
APRE icon
3
Aprea Therapeutics
APRE
$7.6M
$44.6M 8.17%
92,711
– –
FLXN
4
DELISTED
Flexion Therapeutics, Inc.
FLXN
$40M 7.32%
+3,842,578
New +$47.1M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.88B
$31.8M 5.82%
2,030,616
– –
AKRO
6
DELISTED
Akero Therapeutics
AKRO
$23.9M 4.38%
777,727
-1,337,727
-63% -$46.8M
OCUL icon
7
Ocular Therapeutix
OCUL
$1.85B
$16.9M 3.09%
2,215,384
– –
GRTS
8
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$8.22M 1.51%
3,102,929
– –
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$3.94M 0.72%
543,753
– –
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
$594K 0.11%
101,855
– –
VANI icon
11
Vivani Medical
VANI
$113M
$484K 0.09%
187,204
– –
VCYT icon
12
Veracyte
VCYT
$4.44B
– –
-1,205,407
Closed -$31.2M
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,724,909
Closed -$8.8M

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q3 2020 Portfolio in Review

As of Q3 2020, Versant Venture Management held 13 positions worth $546M, down 22% from $696M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $88.6M in Q3 2020, closing 2 positions and reducing 2 holdings. Its most notable exit was Veracyte, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Versant Venture Management opened a new position in Flexion Therapeutics, Inc. worth $40M.

  • Versant Venture Management's largest Q3 2020 buy was Flexion Therapeutics, Inc.: 3,842,578 shares worth $40M.
  • Versant Venture Management's biggest Q3 2020 reduction was CRISPR Therapeutics, cutting an estimated $48.9M.
  • Versant Venture Management fully exited Veracyte in Q3 2020, selling an estimated $31.2M.
  • Versant Venture Management's ten largest holdings make up 100% of its $546M portfolio in Q3 2020.
  • Versant Venture Management opened 1 new position and closed 2 in Q3 2020.
  • Versant Venture Management's portfolio value fell 22% quarter-over-quarter to $546M.

Based on Versant Venture Management's 13F filing for Q3 2020, filed 12 Nov 2020.